• A placebo-controlled, double-blind multicenter trial was conducted in 123 patients with severe hypertension to examine the efficacy and safety of intravenously administered nicardipine hydrochloride in controlling blood pressure. Seventy-three patients were initially randomized to receive nicardipine treatment. This group had an initial blood pressure of 213±3/126±2 mm Hg. Sixty-seven patients achieved the therapeutic goal (diastolic blood pressure 95 mm Hg; systolic blood pressure ≤160 mm Hg). Fifty patients were randomized to receive placebo solution. Blood pressure in these patients was 216±3/125±2 mm Hg. No patient in this group achieved the therapeutic goal during the "blinded" portion of the study. Forty-four of 49 patients who did not respond to placebo administration responded to subsequent treatment with nicardipine. Patients with end-organ damage were included in the study. These included patients with left ventricular hypertrophy, retinopathy, and renal insufficiency. Patients with and without end-organ damage responded equally well to nicardipine treatment. Serious adverse experiences were infrequent, the most common adverse reaction being headache in 24% of the patients studied.
(Arch Intern Med. 1989;149:2662-2669)
Wallin JD, Fletcher E, Ram CVS, et al. Intravenous Nicardipine for the Treatment of Severe Hypertension: A Double-blind, Placebo-Controlled Multicenter Trial. Arch Intern Med. 1989;149(12):2662–2669. doi:10.1001/archinte.1989.00390120034008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: